Biohaven Ltd. (NYSE:BHVN) Director John W. Childs Buys 29,000 Shares

Biohaven Ltd. (NYSE:BHVN) Director John W. Childs purchased 29,000 shares of the stock in a transaction dated Monday, December 30th. The shares were bought at an average price of $35.94 per share, for a total transaction of $1,042,260.00. Following the completion of the acquisition, the director now owns 2,368,741 shares in the company, valued at $85,132,551.54. This represents a 1.24 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Biohaven Price Performance

Biohaven stock opened at $37.28 on Friday. Biohaven Ltd. has a fifty-two week low of $26.80 and a fifty-two week high of $62.21. The firm has a fifty day moving average price of $44.41 and a two-hundred day moving average price of $41.98. The firm has a market cap of $3.77 billion, a price-to-earnings ratio of -3.99 and a beta of 1.24.

Biohaven (NYSE:BHVN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing the consensus estimate of ($1.67) by ($0.03). As a group, sell-side analysts expect that Biohaven Ltd. will post -8.85 earnings per share for the current year.

Institutional Investors Weigh In On Biohaven

Several hedge funds have recently modified their holdings of BHVN. Farallon Capital Management LLC increased its position in Biohaven by 181.4% during the second quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company’s stock worth $78,028,000 after acquiring an additional 1,449,000 shares during the period. Point72 Asset Management L.P. increased its holdings in shares of Biohaven by 745.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company’s stock worth $74,969,000 after purchasing an additional 1,322,922 shares during the period. Armistice Capital LLC increased its holdings in shares of Biohaven by 74.8% during the 2nd quarter. Armistice Capital LLC now owns 1,396,968 shares of the company’s stock worth $48,489,000 after purchasing an additional 597,705 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of Biohaven by 563.4% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 508,622 shares of the company’s stock valued at $25,416,000 after buying an additional 431,954 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of Biohaven by 85.4% in the third quarter. JPMorgan Chase & Co. now owns 809,448 shares of the company’s stock valued at $40,448,000 after buying an additional 372,737 shares during the period. 88.78% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

BHVN has been the topic of a number of recent research reports. Bank of America boosted their target price on Biohaven from $52.00 to $62.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. Robert W. Baird boosted their price target on Biohaven from $58.00 to $60.00 and gave the company an “outperform” rating in a research note on Monday, September 23rd. JPMorgan Chase & Co. raised their price objective on shares of Biohaven from $55.00 to $68.00 and gave the company an “overweight” rating in a research report on Thursday, October 3rd. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 target price (up from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. Finally, Jefferies Financial Group assumed coverage on shares of Biohaven in a report on Monday, September 16th. They set a “buy” rating and a $57.00 price target on the stock. Thirteen investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $63.00.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.